AstraZeneca (LON:AZN) received a GBX 6,235 ($81.47) price objective from stock analysts at HSBC in a research note issued to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. HSBC’s target price would indicate a potential downside of 8.76% from the stock’s previous close.
A number of other brokerages have also recently issued reports on AZN. UBS Group restated a “sell” rating on shares of AstraZeneca in a report on Monday, September 30th. Jefferies Financial Group raised their target price on AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the stock a “hold” rating in a report on Tuesday. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a report on Friday, September 20th. Societe Generale restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, September 10th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Monday, September 30th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 7,137.81 ($93.27).
AstraZeneca stock traded up GBX 19 ($0.25) during mid-day trading on Thursday, hitting GBX 6,834 ($89.30). The stock had a trading volume of 1,176,273 shares, compared to its average volume of 2,310,000. The stock has a 50-day simple moving average of GBX 7,128.97 and a two-hundred day simple moving average of GBX 6,520.13. The stock has a market capitalization of $89.63 billion and a PE ratio of 39.92. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 8,227.88 ($107.51). The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Cost of Goods Sold (COGS)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.